|
99.1
|
| | Condensed Interim Financial Statements (Unaudited) for the Three and Six Months Ended June 30, 2021 | |
|
99.2
|
| | | |
|
99.3
|
| | | |
|
99.4
|
| | |
| | | |
CARDIOL THERAPEUTICS INC.
(Registrant) |
| |||
| Date: August 16, 2021 | | | By: | | |
/s/ Chris Waddick
|
|
| | | | | | | Chris Waddick | |
| | | | | | | Title: Chief Financial Officer | |
| | |
As at
June 30, 2021 |
| |
As at
December 31, 2020 |
| ||||||
ASSETS | | | | | | | | | | | | | |
Current assets | | | | | | | | | | | | | |
Cash and cash equivalents (note 3)
|
| | |
$
|
32,719,238
|
| | | | $ | 14,025,187 | | |
Accounts receivable
|
| | |
|
113,524
|
| | | | | 5,793 | | |
Other receivables
|
| | |
|
570,660
|
| | | | | 214,130 | | |
Prepaid expenses (note 12)
|
| | |
|
2,173,208
|
| | | | | 347,808 | | |
Prepaid inventory (note 11(iv))
|
| | |
|
339,051
|
| | | | | 339,051 | | |
Inventory
|
| |
-
|
| | | | 17,968 | | | |||
Total current assets
|
| | |
|
35,915,681
|
| | | | | 14,949,937 | | |
Non-current assets | | | | | | | | | | | | | |
Property and equipment (note 4)
|
| | |
|
412,535
|
| | | | | 479,554 | | |
Intangible assets (note 6)
|
| | |
|
421,468
|
| | | | | 463,690 | | |
Total assets
|
| | |
$
|
36,749,684
|
| | | | $ | 15,893,181 | | |
EQUITY AND LIABILITIES | | | | | | | | | | | | | |
Current liabilities | | | | | | | | | | | | | |
Accounts payable and accrued liabilities (note 12)
|
| | |
$
|
2,874,803
|
| | | | $ | 2,466,262 | | |
Current portion of lease liability (note 5)
|
| | |
|
52,203
|
| | | | | 51,915 | | |
Total current liabilities
|
| | |
|
2,927,006
|
| | | | | 2,518,177 | | |
Non-current liabilities | | | | | | | | | | | | | |
Lease liability (note 5)
|
| | |
|
85,255
|
| | | | | 104,651 | | |
Total liabilities
|
| | |
|
3,012,261
|
| | | | | 2,622,828 | | |
Equity (deficiency) | | | | | | | | | | | | | |
Share capital (note 7)
|
| | |
|
85,526,589
|
| | | | | 51,923,471 | | |
Warrants (note 9)
|
| | |
|
5,090,206
|
| | | | | 4,460,728 | | |
Contributed surplus (note 8)
|
| | |
|
10,471,038
|
| | | | | 8,765,773 | | |
Deficit
|
| | |
|
(67,350,410)
|
| | | | | (51,879,619) | | |
Total equity (deficiency)
|
| | |
|
33,737,423
|
| | | | | 13,270,353 | | |
Total equity (deficiency) and liabilities
|
| | |
$
|
36,749,684
|
| | | | $ | 15,893,181 | | |
|
“David Elsley”, Director
|
| |
“Guillermo Torre-Amione”, Director
|
|
| | |
Three Months
Ended June 30, 2021 |
| |
Three Months
Ended June 30, 2020 |
| |
Six Months
Ended June 30, 2021 |
| |
Six Months
Ended June 30, 2020 |
| ||||||||||||
Revenue | | | | | | | | | | | | | | | | | | | | | | | | | |
Sales
|
| | |
$
|
78,760
|
| | | | $ | - | | | | |
$
|
78,760
|
| | | | $ | - | | |
Operating expenses (note 12) | | | | | | | | | | | | | | | | | | | | | | | | | |
Administration
|
| | |
$
|
1,427,133
|
| | | | $ | 714,185 | | | | |
$
|
2,846,721
|
| | | | $ | 1,393,730 | | |
Depreciation of property and equipment (note 4)
|
| | |
|
33,510
|
| | | | | 36,337 | | | | |
|
67,019
|
| | | | | 71,580 | | |
Amortization of intangible assets (note 6)
|
| | |
|
21,111
|
| | | | | 21,111 | | | | |
|
42,222
|
| | | | | 42,222 | | |
Corporate communications, marketing
and investor relations |
| | |
|
1,561,943
|
| | | | | 216,865 | | | | |
|
3,140,622
|
| | | | | 664,237 | | |
Research and development
|
| | |
|
1,899,860
|
| | | | | 818,059 | | | | |
|
4,509,065
|
| | | | | 1,402,312 | | |
Salaries and benefits
|
| | |
|
591,869
|
| | | | | 648,861 | | | | |
|
1,722,078
|
| | | | | 1,160,392 | | |
Transfer agent and regulatory
|
| | |
|
139,990
|
| | | | | 58,386 | | | | |
|
186,607
|
| | | | | 107,608 | | |
Share-based compensation (note 8)
|
| | |
|
826,653
|
| | | | | 1,070,188 | | | | |
|
2,967,945
|
| | | | | 1,818,881 | | |
Loss before other income (expenses)
|
| | |
|
(6,423,309)
|
| | | | | (3,583,992) | | | | |
|
(15,403,519)
|
| | | | | (6,660,962) | | |
Interest income
|
| | |
|
25,480
|
| | | | | 13,904 | | | | |
|
42,304
|
| | | | | 33,692 | | |
Gain (loss) on foreign exchange
|
| | |
|
(163,114)
|
| | | | | (54,430) | | | | |
|
(109,576)
|
| | | | | 46,707 | | |
Other income
|
| | |
|
-
|
| | | | | - | | | | |
|
-
|
| | | | | 7,398 | | |
Net loss and comprehensive loss for the period
|
| | |
$
|
(6,560,943)
|
| | | | $ | (3,624,518) | | | | |
$
|
(15,470,791)
|
| | | | $ | (6,573,165) | | |
Basic and diluted net loss per share (note 10)
|
| | |
$
|
(0.16)
|
| | | | $ | (0.13) | | | | |
$
|
(0.41)
|
| | | | $ | (0.24) | | |
Weighted average number of common shares outstanding
|
| | |
|
40,057,578
|
| | | | | 27,856,029 | | | | |
|
37,346,482
|
| | | | | 26,866,895 | | |
| | |
Six Months
Ended June 30, 2021 |
| |
Six Months
Ended June 30, 2021 |
| ||||||
Operating activities | | | | | | | | | | | | | |
Net loss and other comprehensive loss for the period | | | |
$
|
(15,470,791)
|
| | | | $ | (6,573,165) | | |
Adjustments for: | | | | | | | | | | | | | |
Depreciation of property and equipment
|
| | |
|
67,019
|
| | | | | 71,580 | | |
Amortization of intangible assets
|
| | |
|
42,222
|
| | | | | 42,222 | | |
Share-based compensation
|
| | |
|
2,967,945
|
| | | | | 1,818,881 | | |
Accretion on lease liability
|
| | |
|
6,850
|
| | | | | 8,478 | | |
Shares for services
|
| | |
|
1,092,257
|
| | | | | 20,742 | | |
Research and development expenses to be settled through warrant exercise
|
| |
-
|
| | | | 32,032 | | | |||
Changes in non-cash working capital items: | | | | | | | | | | | | | |
Accounts receivable
|
| | |
|
(107,731)
|
| | | | | 3,730 | | |
Other receivables
|
| | |
|
(356,530)
|
| | | | | 747,966 | | |
Prepaid expenses
|
| | |
|
(1,825,400)
|
| | | | | (477,521) | | |
Inventory
|
| | |
|
17,968
|
| | | | | 191,819 | | |
Accounts payable and accrued liabilities
|
| | |
|
408,541
|
| | | | | 499,367 | | |
Net cash used in operating activities
|
| | |
|
(13,157,650)
|
| | | | | (3,613,869) | | |
Investing activities | | | | | | | | | | | | | |
Purchase of property and equipment | | |
-
|
| | | | (20,102) | | | |||
Net cash used in investing activities
|
| |
-
|
| | | | (20,102) | | | |||
Financing activities | | | | | | | | | | | | | |
Issuance of units | | | |
|
22,003,200
|
| | | | | 17,250,000 | | |
Share issuance costs | | | |
|
(1,378,225)
|
| | | | | (1,113,684) | | |
Issuance of warrants, net of issuance costs | | | |
|
8,147
|
| | |
-
|
| |||
Proceeds from stock options exercised | | | |
|
2,708,249
|
| | |
-
|
| |||
Proceeds from warrants exercised | | | |
|
8,536,288
|
| | |
-
|
| |||
Payment of lease liability | | | |
|
(25,958)
|
| | | | | (24,516) | | |
Net cash provided by financing activities
|
| | |
|
31,851,701
|
| | | | | 16,111,800 | | |
Net change in cash and cash equivalents
|
| | |
|
18,694,051
|
| | | | | 12,477,829 | | |
Cash and cash equivalents, beginning of period
|
| | |
|
14,025,187
|
| | | | | 6,956,203 | | |
Cash and cash equivalents, end of period | | | | $ | 32,719,238 | | | | |
$
|
19,434,032
|
| |
| | |
Share capital
|
| |
Warrants
|
| |
Contributed
surplus |
| |
Deficit
|
| |
Total
|
| |||||||||||||||||||||
| | |
Number
|
| |
Amount
|
| ||||||||||||||||||||||||||||||
Balance, December 31, 2019 | | | | | 25,877,686 | | | | | $ | 39,413,506 | | | | | $ | 1,731,250 | | | | | $ | 4,765,965 | | | | | $ | (31,238,684) | | | | | $ | 14,672,037 | | |
Issuance of units
|
| | | | 6,900,000 | | | | | | 13,446,249 | | | | | | 3,803,751 | | | |
-
|
| |
-
|
| | | | 17,250,000 | | | ||||||
Share issuance costs
|
| |
-
|
| | | | (1,263,357) | | | | | | 149,673 | | | |
-
|
| |
-
|
| | | | (1,113,684) | | | |||||||||
Fair value of warrants expired
|
| |
-
|
| |
-
|
| | | | (35,144) | | | | | | 35,144 | | | |
-
|
| |
-
|
| ||||||||||||
Share-based compensation
|
| |
-
|
| |
-
|
| |
-
|
| | | | 1,818,881 | | | |
-
|
| | | | 1,818,881 | | | ||||||||||||
Shares for services
|
| | | | 6,914 | | | | | | 20,742 | | | |
-
|
| |
-
|
| |
-
|
| | | | 20,742 | | | |||||||||
Fair value of warrants earned
|
| |
-
|
| |
-
|
| | | | 32,032 | | | |
-
|
| |
-
|
| | | | 32,032 | | | ||||||||||||
Net loss and comprehensive loss for the period
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| | | | (6,573,165) | | | | | | (6,573,165) | | | ||||||||||||
Balance, June 30, 2020 | | | | | 32,784,600 | | | | | $ | 51,617,140 | | | | | $ | 5,681,562 | | | | | $ | 6,619,990 | | | | | $ | (37,811,849) | | | | | $ | 26,106,843 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Balance, December 31, 2020 | | | | | 32,860,291 | | | | | $ | 51,923,471 | | | | | $ | 4,460,728 | | | | | $ | 8,765,773 | | | | | $ | (51,879,619) | | | | | $ | 13,270,353 | | |
Issuance of units
|
| | | | 6,112,000 | | | | | | 18,211,000 | | | | | | 3,792,200 | | | |
-
|
| |
-
|
| | | | 22,003,200 | | | ||||||
Issuance of warrants, net of issuance costs
|
| |
-
|
| |
-
|
| | | | 8,147 | | | |
-
|
| |
-
|
| | | | 8,147 | | | ||||||||||||
Share issuance costs
|
| |
-
|
| | | | (1,140,691) | | | | | | (237,534) | | | |
-
|
| |
-
|
| | | | (1,378,225) | | | |||||||||
Options exercised
|
| | | | 956,666 | | | | | | 2,708,249 | | | |
-
|
| |
-
|
| |
-
|
| | | | 2,708,249 | | | |||||||||
Fair value of options exercised
|
| |
-
|
| | | | 1,262,680 | | | |
-
|
| | | | (1,262,680) | | | | | | | | | | | | | | | ||||||
Warrants exercised
|
| | | | 2,672,987 | | | | | | 8,391,527 | | | | | | 144,761 | | | | | | | | | | | | | | | | | | 8,536,288 | | |
Fair value of warrants exercised
|
| |
-
|
| | | | 3,078,096 | | | | | | (3,078,096) | | | | | | - | | | |
-
|
| |
-
|
| |||||||||
Shares for services
|
| | | | 344,650 | | | | | | 1,092,257 | | | |
-
|
| |
-
|
| |
-
|
| | | | 1,092,257 | | | |||||||||
Share-based compensation
|
| |
-
|
| |
-
|
| | | | | | | | | | 2,967,945 | | | | | | | | | | | | 2,967,945 | | | ||||||
Net loss and comprehensive loss for the period
|
| |
-
|
| | | | | | | |
-
|
| |
-
|
| | | | (15,470,791) | | | | | | (15,470,791) | | | |||||||||
Balance, June 30, 2021 | | | | | 42,946,594 | | | | | $ | 85,526,589 | | | | | $ | 5,090,206 | | | | | $ | 10,471,038 | | | | | $ | (67,350,410) | | | | | $ | 33,737,423 | | |
Cost
|
| |
Right-of-
use asset |
| |
Equipment
|
| |
Leasehold
improvements |
| |
Office
equipment |
| |
Computer
equipment |
| |
Total
|
| ||||||||||||||||||
Balance, December 31, 2019 | | | | $ | 200,319 | | | | | $ | 116,578 | | | | | $ | 234,772 | | | | | $ | 52,917 | | | | | $ | 55,772 | | | | | $ | 660,358 | | |
Additions | | |
-
|
| | | | 6,480 | | | | | | 2,476 | | | | | | 12,799 | | | | | | 18,847 | | | | | | 40,602 | | | |||
Balance, December 31, 2020 | | | | | 200,319 | | | | | | 123,058 | | | | | | 237,248 | | | | | $ | 65,716 | | | | | $ | 74,619 | | | | | $ | 700,960 | | |
Balance, June 30, 2021 | | | | $ | 200,319 | | | | | $ | 123,058 | | | | | $ | 237,248 | | | | | $ | 65,716 | | | | | $ | 74,619 | | | | | $ | 700,960 | | |
Accumulated Depreciation
|
| |
Right-of-
use asset |
| |
Equipment
|
| |
Leasehold
improvements |
| |
Office
equipment |
| |
Computer
equipment |
| |
Total
|
| ||||||||||||||||||
Balance, December 31, 2019 | | | | $ | 23,373 | | | | | $ | 23,996 | | | | | $ | 4,192 | | | | | $ | 3,816 | | | | | $ | 20,934 | | | | | $ | 76,311 | | |
Depreciation for the year | | | | | 40,068 | | | | | | 29,056 | | | | | | 50,840 | | | | | | 11,828 | | | | | | 13,303 | | | | | | 145,095 | | |
Balance, December 31, 2020 | | | | $ | 63,441 | | | | | $ | 53,052 | | | | | $ | 55,032 | | | | | $ | 15,644 | | | | | $ | 34,237 | | | | | $ | 221,406 | | |
Depreciation for the period | | | | | 20,034 | | | | | | 10,501 | | | | | | 25,420 | | | | | | 5,007 | | | | | | 6,057 | | | | | | 67,019 | | |
Balance, June 30, 2021 | | | | $ | 83,475 | | | | | $ | 63,553 | | | | | $ | 80,452 | | | | | $ | 20,651 | | | | | $ | 40,294 | | | | | $ | 288,425 | | |
Carrying value
|
| |
Right-of-
use asset |
| |
Equipment
|
| |
Leasehold
improvements |
| |
Office
equipment |
| |
Computer
equipment |
| |
Total
|
| ||||||||||||||||||
Balance, December 31, 2020 | | | | $ | 136,878 | | | | | $ | 70,006 | | | | | $ | 182,216$ | | | | | | 50,072 | | | | | $ | 40,382 | | | | | $ | 479,554 | | |
Balance, June 30, 2021 | | | | $ | 116,844 | | | | | $ | 59,505 | | | | | $ | 156,796$ | | | | | | 45,065 | | | | | $ | 34,325 | | | | | $ | 412,535 | | |
| | |
Carrying
Value |
| | | | | | | |||
Balance, December 31, 2019 | | | | $ | 190,752 | | | |
|
| |||
Repayments | | | | | (50,472) | | | |
|
| |||
Accretion | | | | | 16,286 | | | | | | | | |
Balance, December 31, 2020 | | | | $ | 156,566 | | | |
|
| |||
Repayments | | | | | (25,958) | | | |
|
| |||
Accretion | | | | | 6,850 | | | | | | | | |
Balance, June 30, 2021 | | | | $ | 137,458 | | | |
|
| |||
Current portion | | | | | 52,203 | | | | | | | | |
Long-term portion | | | | $ | 85,255 | | | | | | | |
Cost
|
| |
Exclusive global
license agreement |
| | | | | | | |||
Balance, December 31, 2019, December 31, 2020, and June 30, 2021 | | | | $ | 767,228 | | | | | | | |
Accumulated Amortization
|
| |
Exclusive global
license agreement |
| | | | |||
| | | | | | | | |
|
|
Balance, December 31, 2019 | | | | $ | 219,094 | | | | | |
Amortization for the year | | | | | 84,444 | | | | | |
Balance, December 31, 2020 | | | | $ | 303,538 | | | | | |
Amortization for the period | | | | | 42,222 | | | | | |
Balance, June 30, 2021 | | | | $ | 345,760 | | | | | |
Carrying Value
|
| |
Exclusive global
license agreement |
| | | | | | | |||
Balance, December 31, 2020 | | | | $ | 463,690 | | | | | | | | |
Balance, June 30, 2021 | | | | $ | 421,468 | | | | | | | |
| | |
Number of
common shares |
| |
Amount
|
| ||||||
Balance, December 31, 2019 | | | | | 25,877,686 | | | | | $ | 39,413,506 | | |
Issuance of units (ii)
|
| | | | 6,900,000 | | | | | | 17,250,000 | | |
Shares for services (i)
|
| | | | 6,914 | | | | | | 20,742 | | |
Share issuance costs (ii)
|
| |
-
|
| | | | (1,263,357) | | | |||
Fair value of warrants (note 9)
|
| |
-
|
| | | | (3,803,751) | | | |||
Balance, June 30, 2020 | | | | | 32,784,600 | | | | | $ | 51,617,140 | | |
Balance, December 31, 2020 | | | | | 32,860,291 | | | | | $ | 51,923,471 | | |
Shares for services (iii)
|
| | | | 344,650 | | | | | | 1,092,257 | | |
Issuance of units (iv)
|
| | | | 6,112,000 | | | | | | 22,003,200 | | |
Fair value of warrants (iv)
|
| |
-
|
| | | | (3,792,200) | | | |||
Stock options exercised (note 8)
|
| | | | 956,666 | | | | | | 2,708,249 | | |
Fair value of stock options exercised (note 8)
|
| |
-
|
| | | | 1,262,680 | | | |||
Warrants exercised (note 9)
|
| | | | 2,672,987 | | | | | | 8,391,527 | | |
Fair value of warrants exercised (note 9)
|
| |
-
|
| | | | 3,078,096 | | | |||
Share issuance cost (iv)
|
| |
-
|
| | | | (1,140,691) | | | |||
Balance, June 30, 2021 | | | | | 42,946,594 | | | | | $ | 85,526,589 | | |
| | |
Number of
stock options |
| |
Weighted average
exercise price ($) |
| ||||||
Balance, December 31, 2019 | | | | | 1,760,000 | | | | | $ | 4.68 | | |
Issued | | | | | 659,300 | | | | | | 2.77 | | |
Expired | | | | | (100,000) | | | | | | 5.34 | | |
Balance, June 30, 2020 | | | | | 2,319,300 | | | | | $ | 4.11 | | |
Balance, December 31, 2020 | | | | | 2,861,300 | | | | | $ | 3.78 | | |
Issued | | | | | 1,646,666 | | | | | | 4.78 | | |
Expired | | | | | (90,000) | | | | | | 2.84 | | |
Exercised | | | | | (956,666) | | | | | | 2.83 | | |
Balance, June 30, 2021 | | | | | 3,461,300 | | | | | $ | 4.41 | | |
| | |
Six Months
Ended June 30, 2021 |
| |
Six Months
Ended June 30, 2020 |
| ||||||
Fair value of stock options at grant date | | | | $ | 2.25 | | | | | $ | 1.44 | | |
Share price | | | | $ | 4.31 | | | | | $ | 2.77 | | |
Exercise price | | | | $ | 4.31 | | | | | $ | 2.77 | | |
Risk-free interest rate | | | | | 0.44% | | | | | | 0.48% | | |
Expected volatility | | | | | 88% | | | | | | 90% | | |
Expected life in years | | | | | 2.91 | | | | | | 2.42 | | |
Expected dividend yield | | | | | Nil | | | | | | Nil | | |
Expiry date
|
| |
Exercise
price ($) |
| |
Weighted average
remaining contractual life (years) |
| |
Number of
options outstanding |
| |
Number of
options vested (exercisable) |
| | | | ||||||||||||
June 22, 2022 | | | | | 2.58 | | | | | | 0.98 | | | | | | 83,334 | | | | | | 83,334 | | | |
|
|
February 8, 2023 | | | | | 4.56 | | | | | | 1.61 | | | | | | 416,666 | | | | | | 416,666 | | | | ||
February 18, 2023 | | | | | 4.80 | | | | | | 1.64 | | | | | | 560,000 | | | | | | 327,500 | | | | ||
February 22, 2023 | | | | | 4.46 | | | | | | 1.65 | | | | | | 130,000 | | | | | | 55,000 | | | | ||
October 15, 2024 | | | | | 3.23 | | | | | | 3.30 | | | | | | 110,000 | | | | | | 36,667 | | | | ||
December 2, 2024 | | | | | 4.08 | | | | | | 3.43 | | | | | | 60,000 | | | | | | 20,000 | | | | ||
December 5, 2024 | | | | | 3.69 | | | | | | 3.44 | | | | | | 60,000 | | | | | | 45,000 | | | | ||
February 23, 2025 | | | | | 3.54 | | | | | | 3.65 | | | | | | 86,300 | | | | | | 86,300 | | | | ||
August 16, 2025 | | | | | 5.00 | | | | | | 4.13 | | | | | | 200,000 | | | | | | 200,000 | | | | ||
August 19, 2025 | | | | | 2.12 | | | | | | 4.14 | | | | | | 100,000 | | | | | | - | | | | ||
August 30, 2025 | | | | | 5.00 | | | | | | 4.17 | | | | | | 580,000 | | | | | | 423,330 | | | | ||
October 7, 2025 | | | | | 2.90 | | | | | | 4.27 | | | | | | 35,000 | | | | | | - | | | | ||
December 2, 2025 | | | | | 2.59 | | | | | | 4.43 | | | | | | 130,000 | | | | | | - | | | | ||
January 2, 2026 | | | | | 4.30 | | | | | | 4.51 | | | | | | 150,000 | | | | | | 150,000 | | | | ||
January 24, 2026 | | | | | 5.34 | | | | | | 4.57 | | | | | | 60,000 | | | | | | 40,000 | | | | ||
March 29, 2026 | | | | | 4.51 | | | | | | 4.75 | | | | | | 400,000 | | | | | | - | | | | ||
April 1, 2026 | | | | | 5.77 | | | | | | 4.76 | | | | | | 140,000 | | | | | | 93,333 | | | | ||
April 4, 2026 | | | | | 5.42 | | | | | | 4.76 | | | | | | 60,000 | | | | | | 40,000 | | | | ||
May 12, 2026 | | | | | 3.00 | | | | | | 4.87 | | | | | | 100,000 | | | | | | - | | | | | |
| | | | | 4.41 | | | | | | 3.36 | | | | | | 3,461,300 | | | | | | 2,017,130 | | | | | |
| | |
Number of
warrants |
| |
Amount
|
| ||||||
Balance, December 31, 2019 | | | | | 4,212,026 | | | | | $ | 1,731,250 | | |
Issued (note 7 (ii)) | | | | | 3,744,000 | | | | | | 3,953,424 | | |
Expired | | | | | (13,482) | | | | | | (35,144) | | |
Earned (i) | | |
-
|
| | | | 32,032 | | | |||
Balance, June 30, 2020 | | | | | 7,942,544 | | | | | $ | 5,681,562 | | |
Balance, December 31, 2020 | | | | | 4,521,604 | | | | | $ | 4,460,728 | | |
Issued (ii), (note 7 (iv)) | | | | | 3,590,013 | | | | | | 3,707,574 | | |
Exercised | | | | | (2,672,987) | | | | | | (3,078,096) | | |
Balance, June 30, 2021 | | | | | 5,438,630 | | | | | $ | 5,090,206 | | |
Expiry date
|
| |
Exercise
price ($) |
| |
Remaining
contractual life (years) |
| |
Warrants
exercisable |
| |||||||||
June 4, 2022 | | | | | 3.25 | | | | | | 0.93 | | | | | | 1,070,048 | | |
June 4, 2022 (1) | | | | | 2.50 | | | | | | 0.93 | | | | | | 55,182 | | |
August 31, 2022 | | | | | 4.00 | | | | | | 1.14 | | | | | | 824,000 | | |
May 12, 2024 | | | | | 4.60 | | | | | | 2.87 | | | | | | 3,489,400 | | |
| | | | | 4.11 | | | | | | 2.21 | | | | | | 5,438,630 | | |
| | |
Base rent
|
| |
Variable rent
|
| |
Total
|
| | | | | | | |||||||||
2021 | | | | $ | 25,957 | | | | | $ | 25,923 | | | | | $ | 51,880 | | | |
|
| |||
2022 | | | | | 53,934 | | | | | | 51,846 | | | | | | 105,780 | | | |
|
| |||
2023 | | | | | 55,376 | | | | | | 51,846 | | | | | | 107,222 | | | |
|
| |||
2024 | | | | | 23,073 | | | | | | 21,603 | | | | | | 44,676 | | | | | | | | |
| | | | $ | 158,340 | | | | | $ | 151,218 | | | | | $ | 309,558 | | | | | | | |
| 2021 | | | | $ | 873,577 | | |
| 2022 | | | | | 33,049 | | |
| | | | | | 906,626 | | |
| | |
Three Months
Ended June 30, 2021 |
| |
Three Months
Ended June 30, 2020 |
| |
Six Months
E nded June 30, 2021 |
| |
Six Months
Ended June 30, 2020 |
| | | | | | | ||||||||||||
Salaries and benefits | | | |
|
602,769
|
| | | | | 511,213 | | | | |
$
|
1,435,888
|
| | | | $ | 802,588 | | | |
|
| |||
Share-based payments | | | |
|
300,293
|
| | | | | 146,578 | | | | |
|
453,648
|
| | | | | 369,201 | | | | | | | | |
| | | |
|
903,062
|
| | | | | 657,791 | | | | |
$
|
1,889,536
|
| | | | $ | 1,171,789 | | | | | | | |
Use of Proceeds
|
| |
Amount
|
| |
Spent
|
| |
Remaining
|
| |||||||||
Clinical Trials (Phase I and Phase II/III)
|
| | | | 6,400,000 | | | | | | 3,072,628 | | | | | | 3,327,372 | | |
Pre-clinical studies
|
| | | | 900,000 | | | | | | 740,378 | | | | | | 159,622 | | |
Product Development
|
| | | | 1,100,000 | | | | | | 117,546 | | | | | | 928,454 | | |
Marketing & Business Development
|
| | | | 900,000 | | | | | | 87,189 | | | | | | 812,811 | | |
Use of Proceeds
|
| |
Amount
|
| |
Spent
|
| |
Remaining
|
| |||||||||
Phase II/III Clinical Trials in Acute Myocarditis
|
| | | | 6,500,000 | | | | | | 74,250 | | | | | | 6,425,750 | | |
Pre-clinical studies
|
| | | | 1,500,000 | | | | | | — | | | | | | 1,500,000 | | |
Research and Development of Subcutaneous Formulation
|
| | | | 4,000,000 | | | | | | — | | | | | | 4,000,000 | | |
Three Months Ended
|
| |
Total
Revenue ($) |
| |
Profit or (Loss)
|
| |
Total
Assets ($) |
| |||||||||||||||
|
Total
($) |
| |
Per Share(9)
($) |
| ||||||||||||||||||||
June 30, 2021(1)
|
| | | | 78,760 | | | | | | (6,560,943) | | | | | | (0.16) | | | | | | 36,749,684 | | |
March 31, 2021(2)
|
| | | | nil | | | | | | (8,909,848) | | | | | | (0.26) | | | | | | 21,097,832 | | |
December 31, 2020(3)
|
| | | | nil | | | | | | (9,666,527) | | | | | | (0.15) | | | | | | 15,893,181 | | |
September 30, 2020(4)
|
| | | | nil | | | | | | (4,401,243) | | | | | | (0.13) | | | | | | 24,455,341 | | |
June 30, 2020(5)
|
| | | | nil | | | | | | (3,624,518) | | | | | | (0.13) | | | | | | 27,421,000 | | |
March 31, 2020(6)
|
| | | | nil | | | | | | (2,948,647) | | | | | | (0.11) | | | | | | 13,351,298 | | |
December 31, 2020(7)
|
| | | | nil | | | | | | (3,058,709) | | | | | | (0.12) | | | | | | 15,502,865 | | |
September 30, 2019(8)
|
| | | | nil | | | | | | (3,491,816) | | | | | | (0.13) | | | | | | 18,303,737 | | |
Contractual Obligations
|
| |
Total
($) |
| |
Up to 1 year
($) |
| |
1 – 3 years
($) |
| |
4 – 5 years
($) |
| |
After 5
years ($) |
| |||||||||||||||
Amounts payable and other liabilities
|
| | | | 2,874,803 | | | | | | 2,874,803 | | | | | | Nil | | | | | | Nil | | | | | | Nil | | |
Office lease(1)
|
| | | | 309,558 | | | | | | 104,049 | | | | | | 205,509 | | | | | | Nil | | | | | | Nil | | |
Consulting agreements
|
| | | | 906,626 | | | | | | 873,577 | | | | | | 33,049 | | | | | | Nil | | | | | | Nil | | |
Contract research
|
| | | | 1,211,377 | | | | | | 1,211,377 | | | | | | Nil | | | | | | Nil | | | | | | Nil | | |
Total | | | | | 5,302,364 | | | | | | 5,063,806 | | | | | | 238,558 | | | | | | — | | | | | | Nil | | |
| | |
Three months ended
June 30, 2021 ($) |
| |
Three months ended
June 30, 2020 ($) |
| |
Six months ended
June 30, 2021 ($) |
| |
Six months ended
June 30, 2020 ($) |
| ||||||||||||
Salaries and benefits
|
| | | | 602,769 | | | | | | 511,213 | | | | | | 1,435,888 | | | | | | 802,588 | | |
Share-based payments
|
| | | | 300,293 | | | | | | 146,578 | | | | | | 453,648 | | | | | | 369,201 | | |
| | | | | 903,062 | | | | | | 657,791 | | | | | | 1,889,536 | | | | | | 1,171,789 | | |
Expiry date
|
| |
Exercise
price ($) |
| |
Options
outstanding |
| |
Options
exercisable |
| |||||||||
June 22, 2022
|
| | | | 2.58 | | | | | | 83,334 | | | | | | 83,334 | | |
February 8, 2023
|
| | | | 4.56 | | | | | | 416,666 | | | | | | 416,666 | | |
February 18, 2023
|
| | | | 4.80 | | | | | | 560,000 | | | | | | 327,500 | | |
February 23, 2023
|
| | | | 4.46 | | | | | | 130,000 | | | | | | 55,000 | | |
October 15, 2024
|
| | | | 3.23 | | | | | | 110,000 | | | | | | 36,667 | | |
December 2, 2024
|
| | | | 4.08 | | | | | | 60,000 | | | | | | 20,000 | | |
December 5, 2024
|
| | | | 3.69 | | | | | | 60,000 | | | | | | 45,000 | | |
February 23, 2025
|
| | | | 3.54 | | | | | | 86,300 | | | | | | 86,300 | | |
August 16, 2025
|
| | | | 5.00 | | | | | | 200,000 | | | | | | 200,000 | | |
August 19, 2025
|
| | | | 2.12 | | | | | | 100,000 | | | | | | — | | |
August 30, 2025
|
| | | | 5.00 | | | | | | 580,000 | | | | | | 423,330 | | |
October 7, 2025
|
| | | | 2.90 | | | | | | 35,000 | | | | | | — | | |
December 2, 2025
|
| | | | 2.59 | | | | | | 130,000 | | | | | | — | | |
January 2, 2026
|
| | | | 4.30 | | | | | | 150,000 | | | | | | 150,000 | | |
January 24, 2026
|
| | | | 5.34 | | | | | | 60,000 | | | | | | 40,000 | | |
March 29, 2026
|
| | | | 4.51 | | | | | | 400,000 | | | | | | — | | |
April 1, 2026
|
| | | | 5.77 | | | | | | 140,000 | | | | | | 93,333 | | |
April 4, 2026
|
| | | | 5.42 | | | | | | 60,000 | | | | | | 40,000 | | |
May 12, 2026
|
| | | | 3.00 | | | | | | 100,000 | | | | | | — | | |
Total | | | | | | | | | | | 3,461,300 | | | | | | 2,017,130 | | |
Expiry date
|
| |
Exercise
price ($) |
| |
Warrants
outstanding |
| ||||||
June 4, 2022
|
| | | | 3.25 | | | | | | 1,070,048 | | |
June 4, 2022(1)
|
| | | | 2.50 | | | | | | 55,182 | | |
August 31, 2022
|
| | | | 4.00 | | | | | | 824,000 | | |
May 12, 2024
|
| | | | 4.60 | | | | | | 3,489,400 | | |
Total | | | | | | | | | | | 5,438,630 | | |
Fiscal year
|
| | | | | | |
2021
|
| | | | 51,880 | | |
2022
|
| | | | 105,780 | | |
2023
|
| | | | 107,222 | | |
2024
|
| | | | 44,676 | | |
Total | | | | $ | 309,558 | | |
Fiscal year
|
| | | | | | |
2021
|
| | | | 873,577 | | |
2022
|
| | | | 33,049 | | |
Total | | | | $ | 906,626 | | |
| | |
Three months ended
June 30, 2021 ($) |
| |
Three months ended
June 30, 2020 ($) |
| |
Six months ended
June 30, 2021 ($) |
| |
Six months ended
June 30, 2020 ($) |
| ||||||||||||
Contract research
|
| | | | 1,619,640 | | | | | | 406,945 | | | | | | 3,856,760 | | | | | | 913,478 | | |
Wages
|
| | | | 143,741 | | | | | | 103,347 | | | | | | 460,620 | | | | | | 183,309 | | |
Supplies
|
| | | | 43,126 | | | | | | 238,524 | | | | | | 48,253 | | | | | | 191,819 | | |
Regulatory
|
| | | | 93,353 | | | | | | 69,243 | | | | | | 143,432 | | | | | | 113,706 | | |
| | | | | 1,899,860 | | | | | | 818,059 | | | | | | 4,509,065 | | | | | | 1,402,312 | | |
| | |
Three months ended
June 30, 2021 ($) |
| |
Three months ended
June 30, 2020 ($) |
| |
Six months ended
June 30, 2021 ($) |
| |
Six months ended
June 30, 2020 ($) |
| ||||||||||||
Administration
|
| | | | 1,427,133 | | | | | | 714,185 | | | | | | 2,846,721 | | | | | | 1,393,730 | | |
Depreciation of property and equipment
|
| | | | 33,510 | | | | | | 36,337 | | | | | | 67,019 | | | | | | 71,580 | | |
Amortization of intangible assets
|
| | | | 21,111 | | | | | | 21,111 | | | | | | 42,222 | | | | | | 42,222 | | |
Corporate communications, marketing and investor relations
|
| | | | 1,561,943 | | | | | | 216,865 | | | | | | 3,140,622 | | | | | | 664,237 | | |
| | |
Three months ended
June 30, 2021 ($) |
| |
Three months ended
June 30, 2020 ($) |
| |
Six months ended
June 30, 2021 ($) |
| |
Six months ended
June 30, 2020 ($) |
| ||||||||||||
Salaries and benefits
|
| | | | 591,869 | | | | | | 648,861 | | | | | | 1,722,078 | | | | | | 1,160,392 | | |
Transfer agent and regulatory
|
| | | | 139,990 | | | | | | 58,386 | | | | | | 186,607 | | | | | | 107,608 | | |
Share-based compensation
|
| | | | 826,653 | | | | | | 1,070,188 | | | | | | 2,967,945 | | | | | | 1,818,881 | | |
| | | | | 4,602,209 | | | | | | 2,765,933 | | | | | | 10,973,214 | | | | | | 5,258,650 | | |
|
Breakdown of Intangible Assets
|
| |
As at
June 30, 2021 ($) |
| |
As at
December 31, 2020 ($) |
| ||||||
Exclusive global license agreement
|
| | | | 767,228 | | | | | | 767,228 | | |
Accumulated amortization
|
| | | | (345,760) | | | | | | (303,538) | | |
Carrying value
|
| | | | 421,468 | | | | | | 463,690 | | |